Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations

Gabriele Nicolini, Nicola Scichilone, Andrea Bizzi, Alberto Papi, Leonardo M. Fabbri

Research output: Contribution to journalArticle

Abstract

Drugs for asthma and other chronic obstructive diseases of the lungs should be preferably delivered by the inhalation route to match therapeutic effects with low systemic exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose inhalers and dry powder inhalers, each characterized by specific inhaler technique and instructions for use. The patient-device interaction is part of the prescribed therapy and can have a relevant impact on adherence and clinical outcomes. The most suitable device should be considered for each patient to assure the correct drug intake and adherence to the prescribed therapy. The development of new drugs/ devices in the past decades improved the compliance with inhaler and possibly drug delivery to the bronchi. The present review focuses on the recently developed beclomethasone/formoterol extrafine fixed combination and technical aspects of drug delivery to the lungs in patient's perspective.

Original languageEnglish (US)
Pages (from-to)855-864
Number of pages10
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number5
StatePublished - 2008
Externally publishedYes

Fingerprint

Beclomethasone
Drug delivery
Asthma
drug
management
Pharmaceutical Preparations
Equipment and Supplies
Nebulizers and Vaporizers
Powders
Dry Powder Inhalers
Metered Dose Inhalers
Lung
Therapeutic Uses
Bronchi
Chronic Obstructive Pulmonary Disease
Inhalation
Formoterol Fumarate
instruction
Disease
Therapeutics

Keywords

  • Beclomethasone
  • Extrafine
  • Formotertol
  • Modulite

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Nicolini, G., Scichilone, N., Bizzi, A., Papi, A., & Fabbri, L. M. (2008). Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations. Therapeutics and Clinical Risk Management, 4(5), 855-864.

Beclomethasone/formoterol fixed combination for the management of asthma : Patient considerations. / Nicolini, Gabriele; Scichilone, Nicola; Bizzi, Andrea; Papi, Alberto; Fabbri, Leonardo M.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 5, 2008, p. 855-864.

Research output: Contribution to journalArticle

Nicolini, G, Scichilone, N, Bizzi, A, Papi, A & Fabbri, LM 2008, 'Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations', Therapeutics and Clinical Risk Management, vol. 4, no. 5, pp. 855-864.
Nicolini, Gabriele ; Scichilone, Nicola ; Bizzi, Andrea ; Papi, Alberto ; Fabbri, Leonardo M. / Beclomethasone/formoterol fixed combination for the management of asthma : Patient considerations. In: Therapeutics and Clinical Risk Management. 2008 ; Vol. 4, No. 5. pp. 855-864.
@article{db9f58687f70431a83f77bc456a637f6,
title = "Beclomethasone/formoterol fixed combination for the management of asthma: Patient considerations",
abstract = "Drugs for asthma and other chronic obstructive diseases of the lungs should be preferably delivered by the inhalation route to match therapeutic effects with low systemic exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose inhalers and dry powder inhalers, each characterized by specific inhaler technique and instructions for use. The patient-device interaction is part of the prescribed therapy and can have a relevant impact on adherence and clinical outcomes. The most suitable device should be considered for each patient to assure the correct drug intake and adherence to the prescribed therapy. The development of new drugs/ devices in the past decades improved the compliance with inhaler and possibly drug delivery to the bronchi. The present review focuses on the recently developed beclomethasone/formoterol extrafine fixed combination and technical aspects of drug delivery to the lungs in patient's perspective.",
keywords = "Beclomethasone, Extrafine, Formotertol, Modulite",
author = "Gabriele Nicolini and Nicola Scichilone and Andrea Bizzi and Alberto Papi and Fabbri, {Leonardo M.}",
year = "2008",
language = "English (US)",
volume = "4",
pages = "855--864",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "5",

}

TY - JOUR

T1 - Beclomethasone/formoterol fixed combination for the management of asthma

T2 - Patient considerations

AU - Nicolini, Gabriele

AU - Scichilone, Nicola

AU - Bizzi, Andrea

AU - Papi, Alberto

AU - Fabbri, Leonardo M.

PY - 2008

Y1 - 2008

N2 - Drugs for asthma and other chronic obstructive diseases of the lungs should be preferably delivered by the inhalation route to match therapeutic effects with low systemic exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose inhalers and dry powder inhalers, each characterized by specific inhaler technique and instructions for use. The patient-device interaction is part of the prescribed therapy and can have a relevant impact on adherence and clinical outcomes. The most suitable device should be considered for each patient to assure the correct drug intake and adherence to the prescribed therapy. The development of new drugs/ devices in the past decades improved the compliance with inhaler and possibly drug delivery to the bronchi. The present review focuses on the recently developed beclomethasone/formoterol extrafine fixed combination and technical aspects of drug delivery to the lungs in patient's perspective.

AB - Drugs for asthma and other chronic obstructive diseases of the lungs should be preferably delivered by the inhalation route to match therapeutic effects with low systemic exposure. Inhaled drugs are delivered to the lungs via different devices, mainly metered dose inhalers and dry powder inhalers, each characterized by specific inhaler technique and instructions for use. The patient-device interaction is part of the prescribed therapy and can have a relevant impact on adherence and clinical outcomes. The most suitable device should be considered for each patient to assure the correct drug intake and adherence to the prescribed therapy. The development of new drugs/ devices in the past decades improved the compliance with inhaler and possibly drug delivery to the bronchi. The present review focuses on the recently developed beclomethasone/formoterol extrafine fixed combination and technical aspects of drug delivery to the lungs in patient's perspective.

KW - Beclomethasone

KW - Extrafine

KW - Formotertol

KW - Modulite

UR - http://www.scopus.com/inward/record.url?scp=56749121960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749121960&partnerID=8YFLogxK

M3 - Article

C2 - 19209268

AN - SCOPUS:56749121960

VL - 4

SP - 855

EP - 864

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 5

ER -